Soleno Therapeutics SLNO Securities Fraud Class Action Lawsuit Update
Kahn Swick & Foti, LLC (“KSF”), along with its partner and former Louisiana Attorney General, Charles C. Foti, Jr., is alerting investors of Soleno Therapeutics, Inc. (“Soleno” or the “Company”) about a filed securities class action lawsuit.
Class Definition:
The lawsuit aims to recover damages for investors who purchased or held Soleno securities and experienced losses due to alleged securities fraud occurring between March 26, 2025, and November 4, 2025. Additional details are available at
https://www.ksfcounsel.com/cases/nasdaqcm-slno/
Investors who may be affected can reach out to KSF Managing Partner Lewis Kahn at 1-877-515-1850 (toll-free), via email at lewis.kahn@ksfcounsel.com , or by visiting the link above for more information.
Case Summary:
According to the complaint, Soleno and certain executives are accused of withholding important information during the class period, in violation of federal securities laws. The allegations claim that the company made misleading statements and/or failed to disclose key facts, including:
Class Definition:
The lawsuit aims to recover damages for investors who purchased or held Soleno securities and experienced losses due to alleged securities fraud occurring between March 26, 2025, and November 4, 2025. Additional details are available at
https://www.ksfcounsel.com/cases/nasdaqcm-slno/
Investors who may be affected can reach out to KSF Managing Partner Lewis Kahn at 1-877-515-1850 (toll-free), via email at lewis.kahn@ksfcounsel.com , or by visiting the link above for more information.
Case Summary:
According to the complaint, Soleno and certain executives are accused of withholding important information during the class period, in violation of federal securities laws. The allegations claim that the company made misleading statements and/or failed to disclose key facts, including:
- The Phase 3 clinical trials for DCCR—its sole commercial product intended to treat hyperphagia in individuals with Prader-Willi syndrome (PWS)—allegedly downplayed, misrepresented, or omitted significant evidence of safety concerns, including signs of excessive fluid retention in participants.
- As a result, the treatment may have posed greater safety risks than what the company disclosed publicly.
- Consequently, DCCR’s commercial prospects were potentially overstated, while risks such as adverse side effects, higher discontinuation rates, reduced patient uptake, physician hesitation, possible regulatory challenges, and reputational or legal consequences were not fully revealed.
The case is titled City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., No. 26-cv-01979.
Next Steps:
If you invested in Soleno during the specified period and incurred losses, you may apply to be appointed as lead plaintiff by May 5, 2026. However, participation in any potential recovery does not depend on serving in that role.
Next Steps:
If you invested in Soleno during the specified period and incurred losses, you may apply to be appointed as lead plaintiff by May 5, 2026. However, participation in any potential recovery does not depend on serving in that role.
Companies